Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 22 (RPL23AP22)
- Target
- RPL23AP22
- Molecular classification
- Other (Pseudogene)
01
Overview
Ribosomal protein L23a pseudogene 22 (RPL23AP22) is a processed pseudogene located in the human genome. It is a non-functional copy of the ribosomal protein L23a gene (RPL23A) and does not encode an active protein. Pseudogenes like RPL23AP22 arise through gene duplication or retrotransposition events and typically lack regulatory elements or coding potential required for protein synthesis. The canonical parent protein, ribosomal protein L23a, is a structural component of the 60S large ribosomal subunit, but RPL23AP22 itself is not expressed as a protein and is not considered to have a direct role in cellular processes or disease as an active gene product.
- Other names
- RPL23A_2_142RPL23AP22[2][6]
02
Mechanism of action
None (pseudogene; does not encode a druggable target)
03
Biological functions
Other (Pseudogene; no known biological function as a protein-coding gene)
04
Disease associations
Other (No direct disease association for this specific pseudogene. Parent gene RPL23A protein has been implicated in autoimmune responses.)
Beyond the preview
Go deeper on Ribosomal protein L23a pseudogene 22 (RPL23AP22).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 22 (RPL23AP22).